Carmot Therapeutics has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen worth up to $240 million. Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas. Carmot and Amgen will work together to select therapeutic targets and identify drug candidates, while Amgen will be solely responsible for clinical ...